期刊
BRAIN RESEARCH BULLETIN
卷 85, 期 3-4, 页码 231-237出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2011.03.011
关键词
PPAR gamma; Pioglitazone; NF-kappa B; NOS; Acetylation; Huntington's disease
The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the PPAR family. PPAR gamma is the target of insulin-sensitising thiazolidinediones (TZDs), drugs used for the treatment of non-insulin-dependent diabetes. Recently, several studies have shown that PPAR gamma activators can also prevent or attenuate neurodegeneration. The PPAR gamma agonist pioglitazone provides neuroprotection to dopaminergic neurons in lipopolysaccharide (LPS) and MPTP-induced Parkinson's disease experimental models. Here, we investigated whether PPAR gamma activation by pioglitazone protected striatal cells from mitochondrial dysfunction and oxidative stress in a 3 nitropropionic acid (3NP)-induced experimental model of Huntington's disease (HD). Our results suggested that pioglitazone has beneficial effects on mitochondrial dysfunction by interfering with the NF-kappa B signalling pathway, which has been implicated in the pathogenesis of HD. Additionally, we demonstrated that the nuclear translocation of HDAC3 is regulated by 3NP via I kappa B alpha and that treatment with pioglitazone prevented these effects. These results suggested that I kappa B alpha-dependent nuclear translocation is responsible for PPAR gamma inhibition by 3NP and pointed to histone modifications as a novel approach for treating HD. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据